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Abstract
Aims/hypothesis Type 1 diabetes results from the autoim-
mune destruction of pancreatic beta cells. Exogenous insulin
therapy cannot achieve precise physiological control of blood
glucose concentrations, and debilitating complications devel-
op. Lentiviral vectors are promising tools for liver-directed
gene therapy. However, to date, transduction rates in vivo
remain low in hepatocytes, without the induction of cell
cycling. We investigated long-term transgene expression in
quiescent hepatocytes in vitro and determined whether the
lentiviral delivery of furin-cleavable insulin to the liver could
reverse diabetes in rats.
Materials and methods To improve transduction efficiency
in vitro, we optimised hepatocyte isolation and maintenance
protocols and, using an improved surgical delivery method,
delivered furin-cleavable insulin alone or empty vector to
the livers of streptozotocin-induced diabetic rats by means
of a lentiviral vector. Rats were monitored for changes in
body weight and blood glucose, and intravenous glucose
tolerance tests were performed. Expression of insulin was
determined by RT-PCR, immunohistochemistry and elec-
tron microscopy.
Results We achieved long-term transgene expression in
quiescent hepatocytes in vitro (87±1.2% transduction
efficiency), with up to 60±3.2% transduction in vivo. We
normalised blood glucose for 500 days—a significantly
longer period than previously reported—making this the
first successful study using a lentiviral vector. This
procedure resulted in the expression of genes encoding
several beta cell transcription factors, some pancreatic
endocrine transdifferentiation, hepatic insulin storage in
granules, and restoration of glucose tolerance. Liver
function tests remained normal. Importantly, pancreatic
exocrine transdifferentiation did not occur.
Conclusions/interpretation Our data suggest that this regi-
men may ultimately be employed for the treatment of type
1 diabetes.
Keywords Betacelltranscriptionfactors.Genetherapy.
Hepatocytes.Insulinstorage.Lentiviralvector.
Type1diabetes.Wistarrats
Abbreviations
AST aspartate transaminase
ALT alanine aminotransferase
CK18 cytokeratin 18
EGFP enhanced green fluorescent protein
FFO intervallic infusion in full flow occlusion
HMD lentiviral vector HIV/ MSCV
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Introduction
Type 1 diabetes mellitus is caused by autoimmune destruction
of pancreatic beta cells [1]. Treatment requires daily injections
of insulin to normalise blood glucose levels. Tight glucose
control delays, but does not prevent, the onset of complica-
tions, which increase morbidity and mortality. Transplantation
therapy is limited by the scarcity of donors and chronic
immunosuppressive regimens [2]. Physiological glucose
control could be achieved by genetically engineering surro-
gate beta cells that are capable of synthesising, storing and
secreting insulin in response to metabolic signals.
One approach to liver-directed gene therapy of diabetes is
the transcriptional control of insulin expression without the
inductionofstorage[3, 4], which is nonresponsive to minute-
to-minute fluctuations in blood glucose. Another strategy is
the delivery of beta cell transcription factors to the liver to
induce pancreatic transdifferentiation. Studies have
employed transiently expressing adenoviral vectors to
deliver pancreatic and duodenal homeobox gene 1 (Pdx1)
and neurogenic differentiation gene 1 (Neurod1)/betacellulin
gene (Btc)[ 5–8] to streptozotocin (STZ)-induced diabetic
mice and isolated human liver cells, which have resulted in
liver-to-pancreas transdifferentiation and reversal of diabetes.
However, conversion of significant portions of the liver to
‘true’ pancreatic tissue may lead to an increased risk of
autoimmune attack and development of hepatitis, due to the
exocrine differentiating capacity of PDX1 [7].
Most studies on the delivery of genes to the liver have
employed adenoviral vectors [5–8] due to their ability to
efficiently transduce non-dividing cells. However, the
therapeutic gene remains episomal, often with consequent
short-term gene expression and detrimental host immune
responses [9]. Short-term euglycaemia has been achieved
following delivery of insulin via an adeno-associated
vector, with dose-dependent efficacy [10]. Lentiviral vec-
tors (LV) are capable of stably integrating genes into the
chromosomes of dividing and non-dividing cells [9, 11–13].
However, their ability to transduce quiescent hepatocytes
in vivo remains low, as efficient transduction generally
requires induction of cell cycling [14], which can be
achieved by partial hepatectomy [15] or delivery of
hepatotoxins [16, 17].
We have developed an improved method for high
efficiency transduction of rat hepatocytes in vitro and
describe a modified surgical technique for efficient delivery
of LV to rat livers resulting in efficient transduction,
without the requirement for cell division. We have used
this technique to deliver lentivector-encoded furin-cleavable
insulin (INS-FUR) [18], which enables cells to cleave
proinsulin to mature insulin, in the livers of diabetic rats.
This has resulted in permanent reversal of diabetes, insulin
storage and restoration of glucose tolerance.
Materials and methods
Vector production INS-FUR cDNA [18] (proins.IfurIIfur.
B10D; INS-FUR; gift from Genentech, San Francisco, CA,
USA) was cloned into the multi-cloning site of the LV HIV/
MSCV (HMD) [19] (a gift from J. Choi, Department of
Pathology and Laboratory Medicine, University of Pennsyl-
vania, PA, USA) at the EcoRI site to produce the HMD/INS-
FUR construct. This LV vector has an HIV/murine stem cell
virus hybrid long terminal repeat as the promoter and an
internal ribosomal entry site, allowing bicistronic expression
of the genes encoding insulin and enhanced green fluorescent
protein (EGFP) simultaneously. The vectors were produced
by calcium phosphate precipitation cotransfection of three
plasmids (10 μg HMD/INS-FUR or 10 μgp H R ’CMVGFP
[20] expressing EGFP alone, plus 20 μgp C M V ΔR8.2 and
10 μg of the heterologous VSV-G envelope construct
pCVSV-G; all other vector constructs were gifts from I.
Verma, Salk Institute for Biological Sciences, CA, USA) into
293T cells [9]. Conditioned medium was collected 48 h after
transfection, filtered and pelleted (50,000 g). Virus titre was
determined by transducing 293T cells (5×10
5) with serially
diluted vector stocks and quantifying numbers of EGFP-
positive cells by flow cytometry as described [21]. Viral
replication-competency was also assessed.
Transduction of hepatocytes in vitro Maintenance and
experimental manipulation of male Wistar rats (250–300 g;
Gore Hill Research Laboratories, Sydney, NSW, Australia)
were performed in accordance with the NIH principles of
laboratory care and regulations of the Australian Research
Council and were approved by the University of Technology
Sydney. Hepatocytes were isolated using a two-step EDTA/
collagenasedigestion.Theportalvein(PV)andtheabdominal
aorta were cannulated and the liver was flushed in situ with
warmed (40°C) Hanks’ buffered salt solution without Ca
2+
and Mg
2+ (Sigma-Aldrich, Castle Hill, NSW, Australia), plus
1 mmol/l EDTA for 5–7 min. This was followed by
perfusion with 0.05% collagenase (C5138; Sigma-Aldrich)
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2+ and Mg
2+ (Sigma-
Aldrich) for 3–5 min. The hepatocytes were collected,
filtered through sterile 250 and 100 μm mesh and washed
three times in DMEM plus 10% FCS. Preparations contain-
ing greater than 85% viable cells were plated onto Matrigel
(gift from C. Liddle, Westmead Hospital, Sydney, NSW,
Australia) and cultured in DMEM supplemented with
NaHCO3 (44 mmol/l), insulin (100 mU/l), glutamic acid
(2.5 mmol/l), proline (1 mmol/l), ascorbic acid (56 mg/l),
penicillin (100 mg/ml), nicotinamide (10 mmol/l), epidermal
growth factor (20 ng/ml), selenium salts (0.1 μg/ml) and
hydrocortisone (1 nmol/l). After 5 days, 1.5% DMSO
together with CuSO4 (2.5 μg/l), FeSO4.7H2O( 8 3 4μg/l)
and ZnSO4 (1.47 mg/l) was also added to the medium.
Although Matrigel inhibits cell division, hepatocytes were
also irradiated (caesium-137 source; total doses of 0, 10 or
20 Gy) 24 h after seeding and DNA synthesis was assessed
by [
3H]thymidine incorporation [22]. The positive control
was hepatocytes plated on rat-tail collagen 1 (Collaborative
Biomedical Products, Bedford, MA, USA).
At 24 h after cell attachment, hepatocytes (5×10
5 per
well) were transduced with pHR’CMVGFP LV (2.5×10
7
transduction units [TDU]) for 16 h in the presence of
8 μg/ml polybrene. Transduction efficiency was assessed at
2, 7, 14, 21 and 28 days by fluorescence microscopy and
flow cytometry. EGFP-expressing cells were also stained
for the liver-specific marker glucose-6-phosphatase.
Transduction of hepatocytes in vivo Rats were divided into
four groups of 16 animals. For Group 1, the right adrenal vein
wasligatedandsuccessivelytheinfrahepaticvenacava(IVC),
hepatic artery, PVand suprahepatic vena cava were clamped
before pHR’CMVGFP or HMD LV (5×10
8 TDU) was
infused through the PV. During this procedure, blood supply
to the liver was stopped for 5 min and then recommenced for
2 min. This procedure of intervallic infusion in full flow
occlusion (FFO) was repeated three times. Animals in Group
2 were treated similarly; except 0.9% saline was infused. A
70% partial hepatectomy was performed on animals in
Group 3 by resecting the left lateral and median liver lobes.
The right adrenal vein was ligated and LV was infused 24 h
later by the procedure detailed for Group 1. A fourth group
of animals was treated the same as Group 3, except 0.9%
saline was infused. Livers were removed at 1, 2, 4 and
8 weeks. Transduction efficiency was assessed by flow
cytometric quantification of EGFP-positive cells.
To assess cell proliferation, 5-bromo-2′-deoxyuridine
(100 mg/kg; Sigma) was injected intraperitoneally at 18, 28
and 48 h after surgery (partial hepatectomy or sham-operated)
andintountreatedanimals(threeanimalspertime-point).After
2 h, livers were excised and processed by conventional histol-
ogical techniques. Incorporation of 5-bromo-2′-deoxyuridine
was determined by immunohistochemistry.
DiabeteswasinducedbyanintraperitonealinjectionofSTZ
(75 mg/kg body weight; Sapphire Science, Crows Nest, NSW,
Australia). Animals received HMD/INS-FUR or empty HMD
vectoradministered byFFOwithoutpartial hepatectomy. After
treatment, animals were monitored for body weight and blood
glucose. Animals were killed at 60 or 500 days and body
tissues were sampled. To determine the proportion of EGFP-
expressingcells that were hepatocytes, livercells were isolated
and stained with anti-cytokeratin 18 (CK18) antibody (Chem-
icon, Temecula, CA, USA) and R-phycoerythrin-conjugated
secondary antibody (Chemicon). Numbers of insulin-positive
cells were determined using an anti-insulin antibody (Sigma-
Aldrich) and aminomethylcoumarin-conjugated secondary
antibody followed by flow cytometric analysis.
Microscopic analyses Livers and pancreases were collected
60 and 500 days after vector infusion. Islet hormones were
identified by peroxidase immunohistochemistry using dia-
minobenzidine as substrate. Primary antibodies against in-
sulin (BioGenex, San Ramon, CA, USA), glucagon (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) and somato-
statin (Santa Cruz Biotechnology) were used. All cells in
ten random fields were scored. Data were expressed as the
number of positive cells per mm
2 of tissue.
For electron microscopy, tissue was fixed and processed
using uranyl acetate block-staining and lead citrate counter-
staining of ultra-thin sections (80 nm). For insulin immuno-
electronmicroscopy,apost-embeddingimmunogoldprocedure
was used. The beta cell line Nit-1 was the positive control.
Tissues and cells were embedded in LR white and labelling
procedures were performed as previously described [23].
Functional studies Intravenous glucose tolerance tests were
performed on fasted (6–8 h) animals. After infusion of
glucose (0.5 g/kg body weight), blood samples were
collected from the tail vein. Insulin content of pancreas
and liver was determined after acid/ethanol extraction [23].
Insulin and proinsulin in acid/ethanol extractions were
separated on a Sephadex G50 superfine column (Sigma-
Aldrich) [24]. Insulin in serum samples and column fractions
was measured using an RIA for human insulin (Linco
Research, St Charles, MO, USA), which has less than 1
and 6% cross-reactivity with rodent insulin and human
proinsulin, respectively. Commercial RIAs (Linco Research)
were used to measure human and rat C-peptide [25].
To assess liver function, aspartate transaminase (AST)
and alanine aminotransferase (ALT) were measured daily
over the first 10 days and then monthly using commercial
kits (Roche Diagnostics, Castle Hill, NSW, Australia).
PCR analyses For RT-PCR, liver, pancreas, spleen, kidney
and lung were collected at 60 and 500 days after vector
infusion and snap-frozen in liquid nitrogen. Total RNA was
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VIC, Australia). Samples were treated with DNase I (Invi-
trogen). Real-time quantitative PCR was conducted using
SYBR green I and a sequence detection system (ABI 7500
HT; Applied Biosystems, Scoresby, VIC, Australia). Optimal
primer and cDNA template concentrations were determined
by titration. Amplification efficiencies for each primer set
were determined to be similar. Data were represented as
differences between threshold cycle values (ΔCT) for the
transcripts of interest and the internal standard, β-actin. The
expression of the genes encoding human insulin and EGFP
was examined in normal and HMD/INS-FUR-transduced
liver cells using semi-quantitative RT-PCR. Oligonucleotide
sequences are available on request.
Qualitative western blot analyses Nuclear and cytoplasmic
extracts of liver and pancreas were prepared using a nuclear
extraction Kit (Chemicon). Samples (1 μg protein) were
separated by SDS-PAGE and transferred to nitrocellulose.
Primary antibodies against PDX1 and NEUROD1 (Santa
Cruz) were used.
Statistical analyses Differences between groups were de-
termined by Student’s paired t test or, if there were more
than two groups, by one-way analysis of variance after log
transformation of data. Data are expressed as means ±
standard errors (SEM).
Results
Efficient transduction of hepatocytes Isolation of hepato-
cytesbydualperfusionofthePVandabdominalaortaresulted
in increased cell viability as compared with perfusion of the
PV alone (85.7±6.2% vs 67.5±7.8%, respectively, p=0.03).
The cells were morphologically normal, as assessed by light
and electron microscopy, with maintenance of gap junctions
between cells and limited vacuolation. Hepatocytes grown
on Matrigel in the optimised medium, with or without
irradiation, did not undergo cell division, as assessed by
[
3H]thymidine incorporation. Cells grown on collagen,
which enhances cell growth, reached a maximum growth
rate at day 2 and this plateaued between days 5 and 6 (data
not shown). Expression of EGFP was seen 48 h post-
transduction and persisted for over 1 month (Fig. 1a). Up to
87±1.2% of the irradiated cells expressed EGFP (Fig. 1b).
Most EGFP-positive cells (80.2±10.7%) were also positive
for glucose-6-phosphatase, which suggested a hepatocyte
lineage (data not shown). Growth of hepatocytes on collagen
did not increase transduction efficiency. Delivery of HMD/
INS-FUR to hepatocyte cultures resulted in low constitutive
insulin expression (0.2 pmol per 3×10
5 cells) and no insulin
storage; therefore transplantation of hepatocytes transduced
in vitro was not performed.
We delivered pHR’CMVGFP to the livers of diabetic rats
by FFO and compared the transduction efficiency in non-
hepatectomised and partially-hepatectomised animals. The
total wet weights of liver 48 h after partial hepatectomy were
similar to those of non-hepatectomised rats (14.3±0.4 and
14.7±0.8 g, respectively). We also determined whether FFO
stimulated cell division. In control rats, 0.1±0.06% of
hepatocytes were proliferating at 18 h and this rate did not
significantly alter at any time point. At 18 h in animals that
had undergone FFO, 0.3±0.2% of hepatocytes were prolifer-
ating, compared with 0.4±0.3% at 28 h and 0.1±0.04% at
48 h. These values were not significantly different to those
recorded for control animals. By comparison, in animals that
had undergone a partial hepatectomy, 12.8±2.4% of hepato-
cytes were proliferating at18 h. Thisvalue increased to21.4±
4.3% at 28 h and then decreased to 7.4±1.2% at 48 h.
To determine transduction efficiency, liver cells were
isolated after transduction with pHR’CMVGFP and EGFP-
positive cells were assessed by flow cytometry. The maximal
number of EGFP-expressing cells was detected 2 weeks after
transduction (57.0±2%) and was not significantly different
after 2 months (58.2±3.5%). In animals that were partially
hepatectomised prior to transduction, there was no significant
differencein numbersof EGFP-expressing hepatocytes (59.2±
4%) after 2 months compared with non-hepatectomised
animals. Use of the HMD vector also resulted in high levels
of transduction (Fig. 1c). Cells expressing EGFP/INS-FUR
were almost exclusively hepatocytes, as verified by CK18
and insulin labelling (Fig. 1d,e).
Transduction with HMD/INS-FUR reversed STZ-diabetes
Blood glucose levels of STZ-diabetic rats decreased to
subnormal levels immediately after transduction with HMD/
INS-FUR vector (Fig. 2a). By day 5, blood glucose levels of
insulin-transduced animals were not different to non-diabetic
controls and reversal of diabetes was maintained for 500 days
(experimental endpoint). STZ-diabetic rats treated with HMD
alone remained hyperglycaemic until day 60, when they were
killed. The body weights of rats treated with HMD/INS-FUR
were not significantly different to those of non-diabetic controls
until day 125, lower between days 135 and 275, becoming not
significantly different again after day 300 (Fig. 2b). The body
weights of rats treated with the empty vector alone continued to
fall from day 50 to 60. Throughout the experimental period,
there was no elevation of liver enzymes in animals treated with
HMD/INS-FUR (AST: 38.4±6, ALT: 26.9±5 U/l) compared
with control animals (AST: 44.2±16, ALT: 19.1±7).
HMD/INS-FUR transduction stimulated expression of
pancreatic hormones We examined pancreatic hormone-
producing cells in the livers of rats transduced with LVafter
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normal pancreatic islets. By comparison, pancreatic beta
cells were rarely observed in STZ-diabetic animals (1.5±
1.4 cells) (Fig. 3b). Normal liver was negative for insulin
(Fig. 3c), glucagon and somatostatin (not shown). No
pancreatic hormones were detected in livers of animals
treated with empty vector. Following transduction with
HMD/INS-FUR, significant numbers of hepatocytes were
convertedintoinsulin-positivecells(Fig. 3d). There was also
evidence of some pancreatic transdifferentiation, as glucagon-
and somatostatin-positive cells were detected (Fig. 3e,f).
Cells positive for pancreatic hormones were distributed
throughout the livers of animals transduced with HMD/
INS-FUR and not restricted to regions adjacent to the PV.
Fig. 1 EGFP expression in
hepatocytes in vitro and in vivo.
a EGFP expression in primary
hepatocytes in vitro at indicated
times post transduction with
pHR’CMVGFP. Original
magnification: 400×. The insets
show untransduced hepatocytes.
b Flow cytometric analysis of
irradiated (10 Gy), non-dividing
primary hepatocytes 14 days
post-transduction with
pHR’CMVGFP. Negative
control cells show background
fluorescence only. EGFP-
positive cells constituted
87±1.2% of all cells following
transduction. Graphs
representative of three indepen-
dent experiments. c Flow cyto-
metric analysis of liver cells
isolated from a normal control
rat and a rat transduced with the
HMD LV vector 1 month pre-
viously. EGFP-positive cells
constituted 60±3.2% of all liver
cells. The results are
representative of three experi-
ments. d Representative flow
cytometry dot-plot showing the
proportion of EGFP-expressing
cells that were hepatocytes (CK-
18-positive: 58±3.1%) from an
animal that had been transduced
with the HMD/INS-FUR LV
2 months previously and e the
proportion of insulin-positive
(57±2.8%) hepatocytes. Graphs
are representative of three
experiments
1914 Diabetologia (2007) 50:1910–1920Electron microscopy revealed cytoplasmic granules (270–
330 nm in diameter) in liver tissue from animals treated with
HMD/INS-FUR (Fig. 3g). Immunoelectron microscopy of
insulin-producing cells in the liver of STZ-diabetic rats
transduced with HMD/INS-FUR was comparable to those
observed in Nit-1 beta cells (Fig. 3h,i). Inflammatory cell
infiltrationandnecrosiswithintheliversoftransducedanimals
were not observed. Insulin-containing granules were absent in
rats treated with empty vector and in untreated animals.
HMD/INS-FUR transduction induced hepatic insulin
production Insulin storage was 4,165±180 pmol per liver in
HMD/INS-FUR-treated animals, compared with 10,418±
210 pmol in normal rat pancreas (n=3). STZ-treated rat
pancreas only contained 255±110 pmol insulin. Separation
of insulin from proinsulin in liver extracts from animals
treated with HMD/INS-FUR yielded two distinct peaks. The
first represented proinsulin and partially processed material
and the second larger peak corresponded to fully processed
insulin (Fig. 4).
HMD/INS-FUR transduced animals displayed regulated
insulin secretion Therewasnosignificantdifferencebetween
the abilityofSTZ-diabetic animalstransducedwiththe HMD/
INS-FUR vector and untreated animals to normalise blood
glucose levels after delivery of a bolus of intravenous glucose
(Fig. 5a). Levels of human C-peptide and human insulin in
serum samples from HMD/INS-FUR-treated animals
(Fig. 5b,c) were comparable to levels of rat C-peptide and
insulin recorded for non-diabetic animals. Negligible levels
of rat C-peptide were detected in serum from HMD/INS-
FUR-treated STZ-diabetic animals (Fig. 5c).
HMD/INS-FUR transduction stimulated expression of beta
cell transcription factors EGFP expression was only
detected in liver tissue of pHR’CMVGFP- (Fig. 6a) and
HMD-treated (data not shown) rats. Similarly, INS-FUR
expression was restricted to the livers of HMD/INS-FUR-
treated rats (Fig. 6a). Insulin was not detected in livers from
diabetic control animals and diabetic animals injected with
HMD alone (data not shown). Mean ratios of insulin : β-
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Fig. 2 Stable expression of
INS-FUR ameliorated STZ-
induced hyperglycaemia. Blood
glucose concentrations (a) and
body weights (b) of non-diabetic
control rats (black circles) and
STZ-diabetic rats treated with
HMD/INS-FUR (white squares)
or HMD alone (black triangles).
Values are means±SEM (n=5)
Diabetologia (2007) 50:1910–1920 1915actin (1.000±0.069) and EGFP : β-actin (1.088±0.062) in
HMD/INS-FUR liver, determined by semi-quantitative
PCR, were not significantly different. Transduction of
STZ-diabetic rats with the HMD/INS-FUR vector induced
sustained expression of several pancreatic transcription
factors (Fig. 6b). Normal liver and untreated diabetic liver
(not shown) were negative for all pancreatic transcription
factors, while normal pancreas was positive.
Unexpectedly, both Pdx1 and Neurod1 expression were
detected by RT-PCR in empty vector-transduced livers;
however, protein production was not detected (Fig. 6c).
HMD/INS-FUR-transduced livers also expressed the genes
for neurogenin 3 (Neurog3) and Nkx2-2 (Nkx2-2). Gluca-
gon and somatostatin were present in liver transduced with
HMD/INS-FUR (confirmed by immunohistochemistry;
Fig. 3e,f). Pancreatic polypeptide was not expressed. The
transduction of diabetic animals with HMD/INS-FUR did
not result in complete pancreatic transdifferentation of liver
tissue since expression of the rat insulin genes (Ins1, Ins2)
and the genes encoding the insulin prohormone convertase
2( Pc2, also known as Pcsk2) and the exocrine marker p48
(Ptf1a, also known as P48) were not detected (Fig. 6b).
Quantitative real time PCR analysis of the expression levels
of beta cell transcription factors Pdx1 (4.3±0.9), Neurod1
(5.7±1.1) and Neurog3 (7.4±1.8) in HMD/INS-FUR-
treated livers at 500 days indicated that they were lower
Fig. 3 Expression of pancreatic hormones following reversal of STZ-
induced hyperglycaemia. Photomicrographs of anti-insulin staining of
(a) normal pancreas, (b) STZ-diabetic HMD/INS-FUR vector-treated
pancreas, (c) normal liver and (d) STZ-diabetic HMD/INS-FUR
vector-treated liver at 2 months. Photomicrographs of anti-glucagon
(e) and anti-somatostatin (f) staining in STZ-diabetic HMD/INS-FUR
vector-treated liver at 2 months. Positive cells appear brown. Original
magnification: 200×. In a total of 1,200±61 cells the number of
insulin-positive cells (585.6±73.8 cells/mm
2) was fivefold higher than
the number of glucagon-positive cells (109.9±37.1 cells/mm
2) and 11-
fold higher than the number of somatostatin-positive cells (52.2±8.1
cells/mm
2). The number of EGFP-positive cells was 854±80.9 (data
not shown). Therefore, some EGFP-positive cells did not store
pancreatic hormones. No pancreatic hormones were detected in liver
from animals treated with empty vector or from control animals. g
Transmission electron micrograph showing secretory vesicles with
dense granules surrounded by a pale halo (bar: 500 nm). Inset, vesicle
320 nm in diameter. h Immuno-electron micrographs showing local-
isation of insulin in liver 2 months after the transduction of an STZ-
diabetic rat with HMD/INS-FUR and (i) insulin-secreting granules in
Nit-1 beta cells (positive control); bar: 400 nm
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Fig. 4 Stable expression of INS-FUR resulted in production of mature
human insulin. Extracts of rat livers were separated by gel permeation
chromatography and assayed for insulin. Arrows indicate mobility of
mature human insulin (I) (5,800 Da) and proinsulin (pI) (9,400 Da).
Results are representative of three independent experiments
1916 Diabetologia (2007) 50:1910–1920(p<0.001) than levels expressed in normal pancreatic tissue
(Pdx1: 12.5±2.3, NeuroD1: 16.8±1.4, Neurog3: 18.5±2.2).
Discussion
This is the first report of permanent amelioration of STZ-
induced hyperglycaemia using LV delivery of INS-FUR.
Transduced animals processed, stored and secreted insulin
in a glucose-regulated manner. Remission of diabetes, due
to the secretion of insulin from residual beta cells, was
discounted as insulin-positive pancreatic beta cells were
rarely observed and levels of rat C-peptide were negligible.
This is also the first report showing that transduction of
INS-FUR alone can induce expression of several beta cell
transcription factors resulting in hepatocyte differentiation
along a pancreatic lineage.
All previous reports of liver–pancreas transdifferentiation
have been described in cells that endogenously express beta
cell transcription factors [23, 26] or have been engineered
to express these factors, leading to varying degrees of
transdifferentiation [5–8, 27, 28]. Following immediate
reduction in blood glucose due to transgene expression,
induction of long-term euglycaemia in the present study
was probably related to partial hepatic-to-pancreas trans-
differentiation triggered by the lentiviral intrahepatic deliv-
ery method of INS-FUR or from expression of stably
integrated transgene in the host genome. The HMD/INS-
FUR transgene alone, which constitutively expresses
insulin, could not mimic the glucose-sensitive kinetics
demonstrated by IVGTT, nor could it have solely induced
insulin storage. Evidently, the hepatic delivery of the LV
was a key factor, for expression of HMD alone triggered
expression of Pdx1 and Neurod1, if only at the mRNA
level. It is possible that the use of B10-insulin may have
been another factor. This insulin is superior to normal
insulin in biological activity [29] and has some mitogenic
properties [30–32]. However, there was no evidence of
excessive mitogenic activity or tumour development, while
liver function tests remained normal throughout, with no
lymphocytic infiltrates. Parallels can be drawn to the partial
pancreatic transdifferentiation observed in Huh7ins cells,
which endogenously produce NEUROD1 [23] and PDX1
(C. Tao, University of Technology Sydney; unpublished
results). This cell line was transfected with normal human
insulin under the control of a constitutive promoter. After
this, secretory granules developed, which stored di-arginyl
insulin and secreted it in a glucose-responsive manner,
correcting diabetes. However, in Huh7ins cells the expres-
sion of fully processed native insulin was absent. Similarly,
in the present study, pancreatic transdifferentiation was
incomplete, as genes encoding transcription factors such as
NKX6-1 and PAX6, which occur late in the hierarchy; were
not expressed, nor were the rodent insulin genes or the
genes for PC2 pancreatic polypeptide or exocrine markers.
Therefore, the problems encountered with non-selective
pancreatic transdifferentiation, produced after expression of
PDX1 alone [5–7, 33, 34], were not encountered.
How the hepatic delivery of INS-FUR induced the
expression of Pdx1 and other beta cell transcription factors
requires further investigation. Liver and pancreas derive from
common progenitor cells. Transdifferentiation between liver
and pancreas is controlled by only a few transcription factors
[35, 36]. Pdx1 is one such master switch gene. In a recent
study, liver cells producing pancreatic markers (insulin and
PDX1) were induced and localised to areas adjacent to or
within injured tissue areas [37]. Lentiviral transduction may
represent a cellular insult, making progenitor cells permissive
to a pancreatic developmental shift.
The mechanisms that prevented both complete pancre-
atic transdifferentiation and expression of endogenous rat
insulin are yet to be elucidated. Studies on the development
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Fig. 5 Plasma glucose (a), insulin (b) and C-peptide (c) levels after
IVGTT. IVGTTs remained normal for animals maintained for 500 days
(data not shown). White squares, HMD/INS-FUR-treated animals
(60 days) expressing human insulin and human C-peptide; black
diamonds, normal control animals expressing rat insulin and rat C-
peptide; black triangles, rat C-peptide in HMD/INS-FUR-treated
animals. Values are means±SEM (n=5)
Diabetologia (2007) 50:1910–1920 1917of the rat pancreas indicate that chronologically glucagon
and somatostatin appear prior to insulin [38]. The produc-
tion of these pancreatic hormones may have prevented
hypoglycaemia by providing counter-regulatory mecha-
nisms. Complete transdifferentiation into true beta cells
may require additional external factors, such as prolonged
hyperglycaemia [39, 40]. If this is true, then the rapid
reversion to euglycaemia following delivery of the insulin
gene in our study may have prohibited complete liver-to-
pancreas transdifferentiation. Additionally, the expression
of human insulin may have exerted a negative feedback
mechanism to inhibit endogenous insulin expression.
Unlike other studies that have engineered beta cell
neogenesis from liver cells [5–7], the insulin-containing
cells were not isolated to the area surrounding the portal
circulation. Insulin storage was 40% of the insulin content
of a rat pancreas, satisfying clinical requirements for insulin
independence [41]. Corroborating previous studies using
INS-FUR, granules predominately stored fully processed
insulin [18, 42, 43]. EGFP and insulin were produced at
equivalent levels in liver tissue transduced with HMD/INS-
FUR. The majority of cells that expressed EGFP and
insulin were also CK18-positive, indicative of a hepatocyte
lineage for transduced cells.
Despite the lack of the central polypurine tract, LV
pHR’CMVGFP efficiently transduced non-dividing hepato-
cytes in vitro, in the absence of cell division. We obtained an
improvement in transduction efficiency of up to 87% in vitro,
compared with 68% obtained by Zahler et al. [44]. Increased
transduction efficiency may be attributable to several factors,
including: (1) the isolation of hepatocytes by perfusion of
both the PVand abdominal aorta as opposed to the PValone,
the most widely employed procedure [45]; (2) the optimisa-
tion of growth medium; (3) the use of LVat high multiplicity
of infection (50:1); and/or (4) the use of the R8.2 packaging
plasmid, which encodes accessory HIV proteins. The use of
the attenuated plasmid R8.91, used by Zahler et al., resulted
in a 5% reduction in transduction efficiency (B. Ren,
unpublished observations). Similarly, delivery of INS-FUR
in the HMD hybrid vector, which lacks the central
polypurine tract [19], to the portal circulation of STZ-
diabetic rats by FFO resulted in up to 60% transduction of
liver cells, without inducing cell division and with transgene
expression being confined to the liver. The FFO technique,
which employs repeated vector infusion, is probably respon-
sible for the increased transduction efficiency and is more
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Fig. 6 Beta cell transcription factors and pancreatic hormones
expressed in transduced rat livers. a RT-PCR analysis of transcrip-
tion of the genes encoding EGFP or INS-FUR in animals transduced
with pHR’CMVGFP or HMD/INS-FUR LV, respectively: liver (lane
1), pancreas (lane 2), spleen (lane 3), kidney (lane 4) and brain (lane
5) at 60 days. Results for HMD/INS-FUR transduced animals at
500 days were identical (not shown). b RT-PCR analysis of
transcription of the genes for: (1) beta cell transcription factors (Pdx1,
Neurod1, Neurog3, Nkx2-2, Nkx6-1, Pax4, Pax6); (2) the pancreatic
endocrine hormones somatostatin (Sst), glucagon (Gcg) and pancreatic
polypeptide (Ppy); (3) GLUT2 (Slc2a2) and glucokinase (Gck); (4) rat
insulin 1 and 2 (Ins1, Ins2); (5) insulin proconvertase PC2 (Pc2); (6)
the exocrine marker p48 (P48); and (7) β-actin (Actb) in normal liver
(lane 1), liver transduced with HMD alone at 60 days (lane 2), liver
transduced with HMD/INS-FUR LVat 60 days (lane 3) and 500 days
(lane 4), and normal pancreas (lane 5). c Western blot analysis for
PDX1 and NEUROD1 in normal pancreas (lane 1), liver transduced
with HMD/INS-FUR LV at 60 days (lane 2), liver transduced with
HMD alone at 60 days (lane 3) and normal liver (lane 4). PDX1 and
NEUROD1 generated bands at 43 and 50 kDa, respectively
1918 Diabetologia (2007) 50:1910–1920clinically applicable than the widely used perfusion method,
where the IVC is cannulated, thereby increasing the risk of
IVC narrowing and pelvic limb thrombosis [46, 47].
This novel approach offers potential as a beta cell
replacement strategy with diabetic patients serving as their
own donors. Current studies in our laboratory using
nonobese diabetic mice, indicate that this procedure was
able to reverse autoimmune diabetes for 5 months with no
evidence of autoimmune destruction of insulin-secreting
hepatocytes (B. Ren, unpublished observations), giving
hope that this procedure will be useful for reversal of
autoimmune diabetes. There are distinct advantages to the
use of LV for transduction of hepatocytes. LV stably
integrates into the genome of non-dividing cells, including
hepatocytes, and could provide long-lasting expression of
therapeutic genes [48, 49]. Whilst LV integration was not
specifically examined in this study, the longevity of INS-
FUR and EGFP expression provides some evidence for
this. Further, human hepatocytes may be more susceptible
to LV transduction [50] than rodent cells. LV are probably
superior to adenoviral vectors where problems of short-term
expression of genes and immunological responses have
been reported [9]. Adeno-associated vectors are extremely
efficient at transducing mouse livers; however, a recent
study using adeno-associated viral 8-mediated delivery of
Pdx1 did not result in correction of STZ-diabetes in mice
[28]. The unique results reported in this study point to
possible benefits of gene therapy using LV.
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